Media Kit | Insilico Medicine

MEDIA KIT

About

Insilico Medicine

Insilico Medicine ("Insilico") is a global, clinical stage, end-to-end, generative artificial intelligence (AI)-driven biotech company responsible for advancing the first generative AI-discovered and generative AI-designed drug to human clinical trials.

Insilico Medicine was one of the first groups to publish a method that uses a deep adversarial model for new compound generation. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform which works across biology, chemistry, and clinical medicine to identify novel targets and disease hypotheses and to propose novel drug candidates. Using this platform, Insilico has produced a diversified internal pipeline consisting of 31 programs for 29 drug targets, including in fibrosis, cancer, immunology and aging-related disease – including 7 in clinical stages.

The company's lead drug, INS018_055, is a small-molecule drug designed to treat fibrosis-related indications including idiopathic pulmonary fibrosis and the first generative AI-designed drug for an AI-discovered target (TNIK) to reach Phase II trials with patients. The story of this lead drug can be found in a recent publication in Nature Biotechnology, along with extensive data and a customized chatbot for exploring its findings.

More than 40 pharmaceutical companies use Insilico's technology to advance their programs and several are advancing Insilico's AI-designed drugs, and academic researchers have partnered with Insilico to use the company's AI platform to accelerate new treatments for ALS, Alzheimer's disease, and "undruggable" cancer targets.

Insilico Medicine has raised over $400 million in funding. Investors include: Prosperity7 (Aramco's growth venture fund), B Capital Group, Warburg Pincus, BHR Partners, Qiming Ventures, Deerfield, Pavilion Capital, BOLD Capital, Eight Roads, Lilly Asia Ventures, Sinovation Ventures, CPE, OrbiMed, Mirae Asset Capital, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.

"Coding the Impossible Cure"

A documentary that captures our 4-year journey of using generative AI to advance a novel drug from concept to Phase II clinical trials.

Coding the Impossible Cure-Docuthon Insilico Presents

This process is detailed in our paper, "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models," published in Nature Biotechnology. The paper highlights our innovative use of generative AI in drug discovery, extensive in vivo and in vitro validation, and Phase I study results, supporting the potential for this technology to produce safe and effective new drugs — potentially the first AI-developed drug to reach the market.

Access to raw footage used in this documentary:

Please contact Joy Hu at joy.hu@insilico.ai for the password. Docuthon footage →

Executive Team

Alex Zhavoronkov, PhD

Founder and CEO

Alex Zhavoronkov, PhD is the founder and CEO of Insilico Medicine, a leader in generative artificial intelligence technologies for drug discovery and biomarker development. With a combined background in biomedicine and computer technology, he has been recognized by Deep Knowledge Analytics as one of the top 100 AI leaders in drug discovery and advanced healthcare globally.

Alex Aliper, PhD

President

Alex Aliper, PhD, is the President of Insilico Medicine, where he pioneered the application of AI in multi-omics data for drug discovery and drug repurposing. He has built a team of over 100 AI engineers that developed state-of-the-art software products for target discovery.

Feng Ren, PhD

Chief Scientific Officer, Executive Director & Co-CEO

Dr. Feng Ren has extensive experience in the discovery and development of small molecule innovative drugs. He has published over 70 peer-reviewed papers and holds over 100 patents.

Petrina Kamya, PhD

Head of AI Platforms, President of Insilico Medicine Canada

Dr. Petrina Kamya specializes in computational chemistry and AI, overseeing the corporate strategy for AI-driven platforms and services.

Global Presence

Insilico Medicine is a global organization with headquarters in Boston and Hong Kong, with offices and labs in Montreal, Shanghai, Yixing, and Abu Dhabi.

TECHNOLOGY

Commercially-available end-to-end generative AI software and automation platform designed to improve the quality and productivity of pharmaceutical research.

PandaOmics

PandaOmics is a generative AI software designed for therapeutic target and biomarker discovery launched in 2020, integrating generative AI techniques and human expert validation.

Chemistry42

Chemistry42 is a customizable and fully automated software platform launched in 2020 that integrates generative AI algorithms with computational chemistry methods.

InClinico

InClinico is a generative AI-powered software platform utilizing multimodal forecast for predicting the outcome of Phase II clinical trials, demonstrating capabilities with high predictive accuracy.

Partnerships

Insilico Medicine collaborates with a range of pharmaceutical companies and has secured multiple licensing agreements, including with The Menarini Group, Exelixis, and Sanofi. These partnerships are aimed at advancing novel therapies derived from Insilico's AI platform.

Awards

Insilico Medicine has received numerous industry awards, reflecting its leadership in biotech innovation.